secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2021-11-02T23:59:59+00:00
Accession:  0001558370-21-013984
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q3 GAAP net income $181.7M vs loss, revenue $812.9M (+31%); multiple approvals
--------------------------------------------------------------------------------

- Total product & royalty revenues $777.987M, +25% YoY; Jakafi $547.373M (+12%).
- GAAP net income $181.739M ($0.82 diluted EPS) vs net loss $15.203M in Q3 2020.
- Non-GAAP net income $261.824M ($1.18 diluted EPS) vs $50.059M.
- FDA approved Opzelura for atopic dermatitis, Jakafi for chronic GVHD; Minjuvi OK'd in EU.
- Reaffirmed FY2021 guidance: Jakafi net product rev $2,125-$2,170M; R&D $1,350-$1,390M GAAP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000155837021013984/0001558370-21-013984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000155837021013984/incy-20211102x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-013984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer